BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 28

Axsome Therapeutics Inc

AXSMNASDAQ
Trade with Public
Trade with Public
$195.09
-0.94-0.48%
가까이에: Sep 25, 5:00 PM EST
$195.09
N/A
시간외: Sep 25, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Axsome Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Axsome Therapeutics (AXSM).

Price Target Range — 7 Quarters

Analyst Consensus — 20 Analysts

20Buy
Consensus RatingBuy# Analysts20Avg. Consensus PT$235Upside to Avg. PT+20.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026Morgan StanleySean LaamanPT CutEqual-Weight$251→$247
Sep 23, 2026Truist SecuritiesSrikripa DevarakondaPT RaiseBuy$200→$285
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.
Avi Kapoor

PRO
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $306 to $316.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved